INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 07/11/23
BMEA NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Biomea Fusion, Inc.PRNewsWire • 07/11/23
BMEA ALERT: The Law Offices of Vincent Wong Investigate Biomea Fusion, Inc. for Potential Violations of Securities LawsPRNewsWire • 07/10/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 07/08/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 07/07/23
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire • 06/27/23
Biomea Fusion stock soars after release of clinical data on diabetes treatmentMarket Watch • 06/26/23
Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 DGlobeNewsWire • 06/24/23
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023GlobeNewsWire • 06/20/23
Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate HighlightsGlobeNewsWire • 05/02/23
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute LeukemiaGlobeNewsWire • 05/01/23
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in JuneGlobeNewsWire • 04/19/23
Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual MeetingGlobeNewsWire • 04/13/23
Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 04/13/23
Biomea Fusion stock pulls back after $125 million stock offering follows record rallyMarket Watch • 03/29/23
Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate HighlightsGlobeNewsWire • 03/28/23
Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ETGlobeNewsWire • 03/23/23